Syrrx Inc

Takeda Pharmaceutical Co. said Monday that it would acquire Syrrx Inc., a privately held California biotechnology company working on treatments for cancer and diabetes. Takeda, Japan's largest drug maker, will buy San Diego-based Syrrx for about $270 million in cash, the company said. The purchase of Syrrx will enable Takeda to gain access to innovations in medical research. Takeda had made it clear it was also keen to have a research base in the U.S., the world's largest pharmaceutical market.